Just to get this on the correct heading for the threadAgree with...

Just to get this on the correct heading for the thread

Agree with all that has been said about shaking tubes and the market release..

but at the clinical interface - and you can see this when you watch phlebotomists that the blood samples - I suspect the issue was how much to shake. Undershaking, just the right amount of shaking or overshaking - and they found that overshaking has its problems.

You just wouldnt think that someone collecting a blood sample could get it so wrong ! I am sure that it is the same with any new product that depends on the user...

What is important is how CST responded - whether it is to the shaking issue or the endotoxin issue. They responded quickly and definitively and the video is excellent. Market experience in Japan with the shaking lead to the video and now that is used for the rest of the market.

Interesting to think about T spot in this context. Apart from the hassles at the Laboratory level with it being more complex and harder to batch, ... ... and then you have the centralised testing - send in the sample in the special pack... why is that ? I guess they dont have the market uptake that we see with QFT.

Have a look at funds raised to get the product to market...In practical terms - they cannot compete for the biggest market of latent Tb testing at the coalface.

I think that they are finding it is hard to